Irbesartan Combix

Irbesartan, the active ingredient in Irbesartan Combix, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan Combix belongs to the Angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria associated with diabetic kidney disease: reduces urinary protein excretion, supporting renal protection.

Common side effects are generally mild and transient.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated potassium levels in the blood. - Upper respiratory tract infection: nasopharyngitis or mild cough. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Acute renal impairment: sudden decline in kidney function. - Hepatic injury: signs of liver dysfunction such as jaundice. - Severe hypotension: markedly low blood pressure causing faintness or shock.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor relevant parameters.

- Blood pressure monitoring: check regularly to ensure therapeutic control. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Serum potassium surveillance: monitor especially when combined with potassium‑sparing agents. - Hepatic impairment caution: adjust use in patients with liver disease. - Pregnancy avoidance: discontinue if pregnancy is confirmed or planned. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal dysfunction. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): heightens risk of hyperkalemia. - NSAIDs (high‑dose or chronic): can impair renal function and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Lithium: increased lithium levels and potential toxicity. - CYP3A4 inhibitors (e.g., ketoconazole): may raise irbesartan plasma concentrations.